To further promote the clinical use of urinary LASP1 as biomarker for urothelial carcinoma of the bladder regarding limitations and alternative testing systems.
Urine stabilization, alternative measurement systems and limitations by erythrocyte contamination and infection were investigated in 246 patients.
Thimerosal allowed sufficient stabilization. Fluorescence-activated cell sorting analysis was not influenced by presence of erythrocytes or leukocytes and reliably urothelial carcinoma of the bladder but cell counts in specimen were low. Cut-off values of <25 leukocytes and <200 erythrocytes/µl resulted in sensitivity, specificity, positive and negative predictive values of 0.59, 0.80, 0.80 and 0.59, respectively.
Hematuria up to 200 erythrocytes/µl but not presence of leukocytes may be tolerated for this promising marker.
Biomarkers in medicine. 2017 Mar 14 [Epub ahead of print]
Elke Butt, Jan Ebbing, Lukas Bubendorf, Peter Ardelt
Institute for Experimental Biomedicine II, University Clinic of Wuerzburg, Germany., Department of Urology, University Hospital Basel, Basel, Switzerland., Department of Pathology, University Hospital Basel, Basel, Switzerland.